Catalog No.
Product Name
Application
Product Information
Citations
-
Apoptosis Inducer
Tubulysin H is a potent apoptosis inducer that functions as an anti-microtubule toxin by inhibiting tubulin polymerization. Isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis, Tubulysin H exhibits exceptional cytotoxicity in mammalian cells, including those that are multidrug-resistant, with low nanomolar IC50 values. Its ability to disrupt microtubule dynamics results in cell cycle arrest and subsequent induction of apoptosis, making it a valuable tool for research in cancer biology and therapeutic development. -
Apoptosis Inducer
Tubulysin E is a potent apoptosis inducer that acts as an anti-microtubule toxin. Isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis, Tubulysin E exhibits remarkable cytotoxicity in mammalian cells, including those resistant to multiple drugs, with calculated IC50 values in the low nanomolar range. The compound effectively disrupts microtubule dynamics by inhibiting tubulin polymerization, leading to cell cycle arrest and subsequent apoptotic cell death. This makes Tubulysin E a valuable tool in cancer research and studies focused on apoptosis mechanisms. -
Anti-inflammatory/Anti-fibrotic Agent
GDC-3280 is an orally active anti-inflammatory and anti-fibrotic agent that operates primarily through the inhibition of the ASK1-p38 MAPK pathway. It effectively mitigates the inflammatory and fibrotic responses associated with silicosis and influences macrophage polarization. GDC-3280 is a valuable tool for research aimed at understanding and developing therapeutic strategies for inflammatory and fibrotic diseases. -
ASK1 Inhibitor
ASK1-IN-1 is a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with a cell IC50 of 138 nM and a biochemical IC50 of 21 nM. This compound is designed to penetrate the central nervous system (CNS) and is suitable for use in research investigating the roles of ASK1 in cellular apoptosis and neurodegenerative disorders. Its inhibitory activity makes it a valuable tool for exploring therapeutic strategies targeting ASK1-related pathways. -
Caspase-3 Fluorogenic Substrate
Ac-DEVD-AFC is a fluorogenic substrate specifically designed for the detection of caspase-3 activity. Upon cleavage by caspase-3, it releases a fluorescent signal, enabling real-time monitoring of apoptosis. This reagent is widely used in cell biology research to evaluate programmed cell death and assess therapeutic effectiveness in various experimental settings. -
Caspase-1/4 Fluorometric Peptide Substrate
Ac-YVAD-AFC is a fluorometric peptide substrate specifically targeting caspase-1 and caspase-4. It exhibits an excitation wavelength of 400 nm and an emission wavelength of 505 nm, making it suitable for assessing caspase activity in various biological samples. This compound is commonly used in research applications focused on apoptosis, inflammation, and disease mechanisms involving these caspases. -
Caspase 8 Substrate
IETDC is a specific substrate for caspase 8, designed to monitor its activity through a bioluminescent assay. Upon cleavage by activated caspase 8, IETDC releases D-cysteine, which subsequently interacts with HCBT to generate firefly luciferin, producing a detectable bioluminescent signal. This reagent is particularly valuable for investigating acute inflammation and understanding the role of caspase 8 in apoptotic signaling pathways. -
Fluorogenic Caspase-8 Substrate
Ac-IETD-AMC is a fluorogenic substrate specifically designed for the detection and quantification of caspase-8 activity. This compound, which includes an acetyl (Ac) moiety, serves as an efficient tool for studying apoptosis and related pathways mediated by caspase-8 and granzyme B. Its application in research allows for precise measurement of caspase-8 activity in various biological contexts, facilitating insights into cell death mechanisms and potential therapeutic targets. -
MDM-2/p53 MDM2 Inhibitor
CTX1 is a selective inhibitor of MDM2, designed to alleviate HdmX-mediated repression of the tumor suppressor protein p53. This compound demonstrates significant anti-cancer activity, particularly in mouse models of acute myeloid leukemia (AML). CTX1 is utilized in research focused on cancer therapeutics and the modulation of p53 pathways. -
MDM-2/p53 MDM2 Inhibitor
p53 and MDM2 proteins-interaction-inhibitor dihydrochloride is a selective inhibitor of the interaction between the tumor suppressor protein p53 and its negative regulator MDM2. This compound enhances p53 activity, highlighting its potential as an anticancer agent by promoting apoptosis in p53-deficient tumors. It is valuable for research applications focused on cancer therapy, cell cycle regulation, and the molecular mechanisms of tumorigenesis. -
p53-MDM2/X Inhibitor
p53-MDM2-IN-4 is a potent inhibitor of the p53-MDM2/X protein interaction, displaying a Ki value of 3.079 μM. This compound effectively disrupts the MDM2-mediated inhibition of p53, promoting the stabilization and activation of the tumor suppressor protein. p53-MDM2-IN-4 holds significant potential in anti-tumor research and therapeutic development targeting cancer's reliance on the p53 pathway. -
p53-MDM2/X Inhibitor
p53-MDM2-IN-1 is an inhibitor of the p53-MDM2/X protein interaction, exhibiting a Ki value of 23.35 µM. This compound is valuable for anti-tumor research, as it disrupts the interaction between p53 and MDM2/X, potentially restoring p53 function in cancer cells. Its application can enhance the understanding of tumor biology and contribute to the development of novel therapeutic strategies targeting this pathway. -
MDM-2/p53 MDM2 Inhibitor
NVP-CGM097 sulfate is a selective inhibitor of the MDM2-p53 interaction, demonstrating an IC50 of 1.7±0.1 nM for human MDM2. This compound effectively disrupts the MDM2-mediated suppression of p53, leading to the activation of p53-dependent pathways. NVP-CGM097 sulfate is utilized in research focused on cancer therapeutics and the modulation of tumor suppressor activities. -
p53 Ubiquitination Inhibitor
Hdm2 E3 ligase inhibitor 1 is a reversible inhibitor targeting the Hdm2 E3 ubiquitin ligase, which regulates the ubiquitination of the p53 tumor suppressor protein. With an IC50 value of 12.7 μM, this compound effectively inhibits the transfer of ubiquitin from preligated Ub-Ubc4 to p53, resulting in the stabilization of p53 protein levels within tumor cells. Its role in preventing p53 ubiquitination positions Hdm2 E3 ligase inhibitor 1 as a valuable tool for research in cancer biology and therapeutic development. -
p53-MDM2 Binding Inhibitor
NU-8231 is a potent inhibitor of the p53-MDM2 interaction, exhibiting an IC50 range of 5.3-200 μM. This compound is instrumental in cancer research, facilitating studies on the restoration of p53 function and the modulation of apoptotic pathways. Its ability to disrupt the p53-MDM2 binding offers potential insights into therapeutic strategies targeting p53-mediated tumor suppression. -
MDM2 Inhibitor
AM-6761 is a highly potent inhibitor of MDM2, exhibiting an IC50 of 0.1 nM. This compound is crucial for studies on cancer biology, particularly in understanding the regulatory mechanisms of p53 and its interactions with MDM2. AM-6761 is primarily used in cancer research to evaluate potential therapeutic strategies targeting MDM2-mediated pathways. -
MDM-2/p53 MDM2 Inhibitor
AM-8735 is a selective inhibitor of the MDM2 protein, targeting its interaction with the p53 tumor suppressor. It exhibits potent activity with an IC50 of 25 nM, making it a valuable tool for cancer research. This compound is utilized in studies investigating the reactivation of p53 in tumor models, offering potential insights into therapeutic strategies for p53-deficient cancers. -
RIPK1 inhibitor
RIPK1-IN-36 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1) with an EC50 of less than 25 nM. This compound is valuable for investigating the role of RIPK1 in various pathological conditions, including inflammatory diseases and neurodegenerative disorders. Researchers can utilize RIPK1-IN-36 to explore the therapeutic potential of targeting RIPK1 signaling pathways in relevant biological models. -
Survivin Inhibitor
LQZ-7I is a potent inhibitor of survivin, specifically targeting its dimerization. By disrupting survivin interactions, LQZ-7I effectively induces cell death and decreases cancer cell viability. This compound demonstrates significant anti-tumor activity in xenograft models, contributing to reduced tumor growth and survivin depletion within tumor tissues, making it valuable for cancer research applications. -
Survivin and Op18 Inhibitor
GDP366 is a dual inhibitor of survivin and Op18, effectively targeting these proteins to impede cancer cell proliferation. This compound demonstrates significant cell growth inhibition, promotes cellular senescence, and induces mitotic catastrophe in human cancer cells. Its mechanism of action makes GDP366 valuable for research related to cancer biology and therapeutic strategies. -
Survivin Inhibitor
LLP-3 is a potent inhibitor of Survivin, targeting the interaction between Survivin and Ran in cancer cells. This compound demonstrates significant potential in the study of Glioblastoma multiforme (GBM), aiding in the understanding of cancer cell viability and proliferation. LLP-3 provides valuable insights into therapeutic strategies aimed at disrupting key survival pathways in tumors. -
Survivin Inhibitor
AQIM-I is a potent inhibitor of survivin, effectively reducing its expression and colony formation in cancer cells. This compound induces reactive oxygen species (ROS) production, leading to apoptosis, cell cycle arrest, DNA damage, and autophagy. AQIM-I demonstrates significant efficacy against non-small cell lung cancer cells A549, exhibiting an IC50 value of 9 nM, making it a valuable tool for investigating survivin-related pathways in cancer research. -
Survivin
Gataparsen is an antisense oligonucleotide that specifically targets survivin mRNA, aiming to inhibit its expression. This intervention has shown potential antitumor activity, making it a valuable tool in cancer research. Gataparsen can be utilized to study the role of survivin in cell survival and proliferation, and to explore therapeutic strategies for tumor suppression. -
Survivin Inhibitor
MX106 is a potent inhibitor of survivin, a protein that plays a critical role in inhibiting apoptosis. This compound demonstrates significant anti-proliferative activity against human melanoma, epidermoid carcinoma, and colon cancer cell lines. Additionally, MX106 effectively targets multidrug-resistant cell lines that overexpress P-glycoprotein, making it a valuable tool for cancer research and the development of novel therapeutic strategies. -
Survivin Inhibitor
Isonanangenine B is a selective inhibitor of survivin, exhibiting an IC50 of 1.6 µM. It effectively obstructs the interaction of critical transcription factors, including Stat3 and NF-κB, with the survivin promoter. This compound holds potential for advancing cancer research, particularly in elucidating the mechanisms of survivin modulation in tumorigenesis. -
Cell-cycle Inhibitor, Senescence Inducer, Apoptosis Inducer, Antiproliferative Agent
Anticancer agent 299 is a cell-cycle inhibitor that functions as a senescence and apoptosis inducer, exhibiting significant antiproliferative effects on cancer cells. This compound demonstrates selective cytotoxicity against cancerous cells with minimal impact on non-tumoral chondrocyte cells at therapeutic concentrations. Anticancer agent 299 is particularly useful for research related to ER+/HER2− breast cancer and BRAF-mutant melanoma. -
ASK1 Inhibitor
ASK1-IN-10 is a selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1), exhibiting an IC50 value of less than 200 nM. In addition to its primary mechanism, ASK1-IN-10 exhibits inhibitory activity against hERG potassium channels. This compound serves as a valuable tool for investigating the role of ASK1 in inflammation-related research and its potential therapeutic implications. -
ASK1 Inhibitor
ASK1-IN-8 is a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with an IC50 value of 1.8 nM. This compound demonstrates significant hepatoprotective effects in experimental models, notably reducing plasma alanine transaminase (ALT) levels in acetaminophen-induced liver injury. ASK1-IN-8 is suitable for research applications focused on liver pathologies and the modulation of apoptosis signaling pathways. -
10-Methoxycamptothecin Prodrug
MG16 is a prodrug of 10-Methoxycamptothecin, primarily targeting CDK6 and ASK1. It effectively induces cell cycle arrest and apoptosis in cancer cells, demonstrating significant anticancer activity against Lewis lung carcinoma, small cell lung cancer, and non-small cell lung cancer. This compound is valuable for research applications focused on cancer therapeutics and the exploration of cell cycle regulation. -
ASK1 Inhibitor
ASK1-IN-9 is a selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with an IC50 value of less than 200 nM. This compound is primarily utilized in research focused on inflammation pathways, offering insights into the role of ASK1 in cellular stress responses and programmed cell death. Its potent inhibitory effects make it a valuable tool for exploring therapeutic strategies in related diseases. -
ASK1 Ligand
ASK1 Ligand 1 is a selective binding ligand for Apoptosis Signal-Regulating Kinase 1 (ASK1). This compound facilitates the development of PROTACs, including dASK1-VHL, enabling targeted protein degradation. Its primary applications lie in studies of apoptosis and signal transduction pathways, making it a valuable tool in cancer research and therapeutic development. -
ASK1 PROTAC Degrader
dASK1 is a selective PROTAC degrader targeting apoptosis signal-regulating kinase 1 (ASK1) through a cereblon (CRBN)-mediated pathway. This compound forms a stable ternary complex with ASK1, promoting its efficient degradation via the ubiquitin-proteasome system. dASK1 exhibits potent activity in degrading ASK1 and serves as a valuable tool in research focused on steatohepatitis and related pathologies. -
ASK1 Inhibitor
ASK1-IN-7 is an inhibitor specifically targeting Apoptosis signal-regulating kinase 1 (ASK1). This compound is derived from a recognized ASK1 inhibitor scaffold and exhibits significant potential in modulating the ASK1 signaling pathway. Its biological activity supports research into cell stress responses, inflammation, neurodegenerative disorders, and cardiovascular diseases. ASK1-IN-7 serves as a valuable tool for understanding the role of ASK1 in various pathophysiological processes. -
DAPK1/ZIPK Inhibitor
HS38 is a selective ATP-competitive inhibitor targeting death-associated protein kinase 1 (DAPK1) and zipper-interacting protein kinase (ZIPK, also known as DAPK3), with Kds of 300 nM and 280 nM, respectively. Additionally, HS38 demonstrates inhibitory activity against PIM3 with an IC50 of 200 nM. This compound is valuable for research into smooth muscle-related disorders, aiding in the understanding of the underlying molecular mechanisms and potential therapeutic pathways. -
DAPK3 Inhibitor
HS148 is a selective inhibitor of Death-associated protein kinase 3 (DAPK3) with a Ki value of 119 nM. This compound effectively modulates DAPK3 activity, making it a valuable tool for studying its role in apoptosis and various signaling pathways. HS148 is suitable for applications in cancer research and investigations into neurodegenerative conditions where DAPK3 is implicated. -
DAPK1 PROTAC Degrader
PROTAC DAPK1 Degrader-1 selectively targets DAPK1 for degradation, exhibiting a DC50 value of 119.6 nM. This compound has been shown to elevate MDM2 protein levels while concurrently decreasing cleaved caspase-3 and cleaved PARP levels in a neurotoxin-induced cell apoptosis model. Its ability to effectively inhibit neuronal apoptosis positions PROTAC DAPK1 Degrader-1 as a valuable tool for investigating neurological disorders, including cerebral ischemia and traumatic brain injury. -
DAPK1 Inhibitor
DAPK1-IN-1 is a selective inhibitor of death-associated protein kinase 1 (DAPK1) with a Kd value of 0.63 μM. This compound exhibits potential in modulating DAPK1 activity, making it a valuable tool for investigating pathways involved in neurodegenerative diseases, particularly Alzheimer’s disease. Researchers can utilize DAPK1-IN-1 to explore its effects on cell death and survival mechanisms in various cellular contexts. -
DAPK Inhibitor
CK156 is a selective inhibitor of death-associated protein kinase (DAPK), exhibiting an IC50 of 182 nM in the DRAK1 NanoBRET assay. Additionally, it shows inhibition of CK2a1 and CK2a2 at concentrations of 34 μM and 39 μM, respectively. This compound is valuable for investigating autoimmune and inflammatory diseases, providing insights into the regulation of cell death and survival pathways. -
DAPK3 Inhibitor
HS94 is a selective inhibitor of DAPK3 (Death-associated protein kinase 3), a serine/threonine kinase involved in various cellular processes, including apoptosis and inflammation. This compound has demonstrated significant biological activity by modulating DAPK3 signaling pathways, making it a valuable tool in hypertension research. Investigating HS94's effects may provide insights into the molecular mechanisms underlying cardiovascular diseases and potential therapeutic approaches. -
DAPK Inhibitor
DAPK-IN-2 is an inhibitor of Death-Associated Protein Kinase (DAPK), a key regulator involved in apoptosis and autophagy. This compound exhibits potential anti-apoptotic properties and is relevant in the study of cerebral infarction and ischemic diseases. Researchers can utilize DAPK-IN-2 to investigate the role of DAPK in cell death pathways and evaluate therapeutic approaches for neuroprotective strategies. -
DAPK1 Degrader
TAT-GluN2BCTM is a membrane-permeable peptide designed to target DAPK1 for degradation. By facilitating the transport of active DAPK1 to lysosomes, this compound effectively reduces its levels, thereby providing protection to neurons against oxidative stress and NMDAR-mediated excitotoxicity. TAT-GluN2BCTM is a valuable tool for research focused on neuroprotection mechanisms. -
GPX4 Allosteric Activator
PKUMDL-LC-101-D04 is an allosteric activator of glutathione peroxidase 4 (GPX4), exhibiting a pEC50 value of 4.7. This compound effectively inhibits ferroptosis and reduces inflammatory responses, making it a valuable tool for research investigating oxidative stress and related pathologies. Its ability to modulate GPX4 activity highlights its potential applications in studies focused on cell survival and neuroprotection. -
Glutathione Peroxidase Inhibitor
4-Aminobenzohydrazide is a potent inhibitor of glutathione peroxidase, demonstrated to induce oxidative stress in neutrophils, with an IC50 value of 43.6 μM for reactive oxygen species (ROS) generation. This compound serves as a valuable tool for investigating oxidative stress-related mechanisms and has applications in subacute stroke research. Its ability to irreversibly inhibit myeloperoxidase further reinforces its utility in studying inflammatory processes and cellular responses. -
Glutathione Peroxidase
Glutathione Peroxidase (GSH-Px; EC 1.11.1.9) is an enzyme from the peroxidase family that catalyzes the reduction of hydrogen peroxide and lipid peroxides, utilizing reduced glutathione (GSH) to produce oxidized glutathione (GSSG). This enzyme plays a critical role in cellular defense against oxidative stress by scavenging reactive oxygen species. Glutathione Peroxidase is widely used in biochemical research to investigate antioxidant mechanisms and the cellular response to oxidative damage. -
Intermediate
GPX4-IN-2 is an intermediate compound related to GPX4-IN-1, which targets glutathione peroxidase 4 (GPX4). This compound exhibits antiproliferative activity, making it a valuable tool in cancer research. Its role in the exploration of GPX4's function and its potential as a therapeutic target in oncology can aid in the development of innovative cancer treatments. -
GPX4 Inhibitor
GPX4-IN-4 is a selective inhibitor of glutathione peroxidase 4 (GPX4). This compound demonstrates significant efficacy in disrupting GPX4 activity, leading to increased oxidative stress and cellular apoptosis. GPX4-IN-4 is particularly relevant for cancer research, as it can help elucidate the role of GPX4 in tumor growth and survival, providing insights for potential therapeutic strategies. -
GPX4-Inhibitor Affinity Probe
ML162-yne is a selective GPX4-inhibitor affinity probe that utilizes click chemistry for targeted interactions. Featuring an alkyne functional group, this reagent can participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), enabling efficient conjugation with azide-containing molecules. This capability makes ML162-yne valuable for studying the role of GPX4 in various biological processes and for developing novel therapeutic strategies. -
Glutathione Peroxidase Inhibitor
Sorbifolin is a flavone glucoside that functions as a potent inhibitor of glutathione peroxidase. It exhibits myeloperoxidase inhibitory activity with an IC50 value of 19.2 nM, along with significant radical scavenging properties. Due to its ability to modulate oxidative stress-related pathways, Sorbifolin is valuable for research applications focusing on inflammatory diseases and redox homeostasis. -
GPX4 Inhibitor
GPX4-IN-15 is a specific inhibitor of GPX4, demonstrating a 19.8% inhibition at a concentration of 1 μM. This compound effectively inhibits the proliferation of various cancer cell lines, including MDA-MB-468, BT-549, and MDA-MB-231, with IC50 values of 0.86 μM, 0.96 μM, and 0.48 μM, respectively. GPX4-IN-15 is a valuable tool for researchers investigating the role of GPX4 in cancer biology and therapeutic resistance. -
GPX4 Inhibitor
GPX4-IN-17 is a selective inhibitor of GPX4, demonstrating potent cytotoxicity with an IC50 of 0.3 nM and high binding affinity (KD = 20.4 nM). This compound effectively inhibits tumor growth in xenograft models while exhibiting minimal cytotoxic effects on normal tissues. GPX4-IN-17 is a valuable tool for enhancing cancer chemotherapy and addressing tumor resistance, making it a significant reagent for antitumor research applications.
